Literature DB >> 18787660

BDNF protein levels are decreased in transformed lymphoblasts from lithium-responsive patients with bipolar disorder.

Michael Tseng1, Martin Alda, Li Xu, Xiujun Sun, Jun-Feng Wang, Paul Grof, Gustavo Turecki, Guy Rouleau, L Trevor Young.   

Abstract

OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is a key factor in neuroplasticity and has been implicated in the affective disorders; studies have demonstrated elevated BDNF in patients taking lithium and other mood stabilizers. The objective of our study was to analyze BDNF in lithium-responsive patients with bipolar disorder (BD) to further understand the role of BDNF in the pathophysiology of BD.
METHODS: Using enzyme-linked immunosorbent assay, we measured transformed B lymphocytes for BDNF protein.
RESULTS: BDNF levels were 36% lower in lymphoblasts from patients with BD (n = 12), compared with matched control participants (n = 13), and 55% lower when compared with their unaffected relatives (n = 14). Lithium significantly decreased BDNF levels in patients with BD and healthy control participants, although BDNF levels remained lower (33%) in the BD group posttreatment.
CONCLUSION: Decreased BDNF may constitute part of the pathophysiologic process of BD in a lithium-responsive subgroup of individuals with this disease. A compensatory mechanism protecting the genetically predisposed unaffected relatives from phenotypic expression of BD is suggested.

Entities:  

Keywords:  bipolar disorder; brain-derived neurotrophic factor; enzyme-linked immunosorbent assay; lithium

Mesh:

Substances:

Year:  2008        PMID: 18787660      PMCID: PMC2527719     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  27 in total

1.  Practice guideline for the treatment of patients with bipolar disorder (revision).

Authors: 
Journal:  Am J Psychiatry       Date:  2002-04       Impact factor: 18.112

2.  Is lithium response related to G(s)alpha levels in transformed lymphoblasts from subjects with bipolar disorder?

Authors:  M Alda; D Keller; E Grof; G Turecki; P Cavazzoni; A Duffy; G A Rouleau; P Grof; L T Young
Journal:  J Affect Disord       Date:  2001-07       Impact factor: 4.839

3.  Brain lithium concentrations measured with lithium-7 magnetic resonance spectroscopy in patients with affective disorders: relationship to erythrocyte and serum concentrations.

Authors:  T Kato; T Shioiri; T Inubushi; S Takahashi
Journal:  Biol Psychiatry       Date:  1993-02-01       Impact factor: 13.382

4.  Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication.

Authors:  B Chen; D Dowlatshahi; G M MacQueen; J F Wang; L T Young
Journal:  Biol Psychiatry       Date:  2001-08-15       Impact factor: 13.382

5.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

6.  Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets.

Authors:  Félicien Karege; Michèle Schwald; Mbaye Cisse
Journal:  Neurosci Lett       Date:  2002-08-16       Impact factor: 3.046

7.  The role of the extracellular signal-regulated kinase signaling pathway in mood modulation.

Authors:  Haim Einat; Peixiong Yuan; Todd D Gould; Jianling Li; JianHua Du; Lei Zhang; Husseini K Manji; Guang Chen
Journal:  J Neurosci       Date:  2003-08-13       Impact factor: 6.167

Review 8.  The phenotypic spectra of bipolar disorder.

Authors:  Martin Alda
Journal:  Eur Neuropsychopharmacol       Date:  2004-05       Impact factor: 4.600

9.  A diagnostic interview: the schedule for affective disorders and schizophrenia.

Authors:  J Endicott; R L Spitzer
Journal:  Arch Gen Psychiatry       Date:  1978-07

10.  The cAMP-dependent protein kinase A and brain-derived neurotrophic factor expression in lymphoblast cells of bipolar affective disorder.

Authors:  Félicien Karege; Michèle Schwald; Philippe Papadimitriou; Christine Lachausse; Mbaye Cissé
Journal:  J Affect Disord       Date:  2004-04       Impact factor: 4.839

View more
  6 in total

1.  Serum Brain-derived Neurotrophic Factor Levels among Euthymic Adolescents with Bipolar Disorder Type I.

Authors:  Nagihan Cevher Binici; Fatma Neslihan Inal Emiroğlu; Halil Resmi; Hülya Ellidokuz
Journal:  Noro Psikiyatr Ars       Date:  2016-09-01       Impact factor: 1.339

2.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 3.  The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

4.  Lithium response in bipolar disorder correlates with improved cell viability of patient derived cell lines.

Authors:  Pradip Paul; Shruti Iyer; Ravi Kumar Nadella; Rashmitha Nayak; Anirudh S Chellappa; Sheetal Ambardar; Reeteka Sud; Salil K Sukumaran; Meera Purushottam; Sanjeev Jain; Biju Viswanath
Journal:  Sci Rep       Date:  2020-05-04       Impact factor: 4.379

5.  Towards the clinical implementation of pharmacogenetics in bipolar disorder.

Authors:  Naji C Salloum; Michael J McCarthy; Susan G Leckband; John R Kelsoe
Journal:  BMC Med       Date:  2014-05-30       Impact factor: 8.775

6.  EGR3 Immediate Early Gene and the Brain-Derived Neurotrophic Factor in Bipolar Disorder.

Authors:  Bianca Pfaffenseller; Flavio Kapczinski; Amelia L Gallitano; Fábio Klamt
Journal:  Front Behav Neurosci       Date:  2018-02-05       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.